A July 2024 study in ‘Nature Aging’ validates p-tau217 blood biomarkers for forecasting Alzheimer’s symptoms within 3-4 years, enhancing early intervention and personalized medicine....
Analytical post exploring CAR-T cell therapy’s potential to treat Alzheimer’s by targeting amyloid plaques, with insights from recent clinical trials and cost-benefit considerations. Innov...
A 2025 research paper finds that obese individuals with low choline levels face increased Alzheimer’s disease risk due to inflammation and neuronal damage, highlighting dietary interventions. Re...
The Phase 3 failure of semaglutide in Alzheimer’s disease highlights challenges in repurposing GLP-1 agonists, urging a shift towards biomarker-driven and personalized approaches in neurodegener...
